Double-antibody cancer therapy shows promise in advanced tumor trial
NCT ID NCT05214482
Summary
This study tested whether combining two experimental immunotherapy drugs (AK112 and AK117) with or without chemotherapy could help control advanced cancers. The trial enrolled 154 adults with various advanced solid tumors including stomach, bile duct, pancreatic, and lung cancers. Researchers measured how well the combination worked and monitored side effects to determine if this approach could help patients whose cancers had progressed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.